New prognostic models in metastatic renal cancer

Currently 7 targeted therapies have been approved for the treatment of advanced RCC: sorafenib, sunitinib, temsirolimus, axitinib, bevacizumab in combination with interferon-α, everolimus and pazopanib (1). There is difficulty distinguishing between them due to lack of head to head studies. Therefore there are multiple treatment options for patients in the first and second line setting.